Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3848575 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| LY3848575 Dose 1 | EXPERIMENTAL | LY3848575 low dose administered subcutaneously (SC). |
| LY3848575 Dose 2 | EXPERIMENTAL | LY3848575 mid dose administered SC. |
| LY3848575 Dose 3 | EXPERIMENTAL | LY3848575 high dose administered SC. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3848575 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a Visual Analog Scale (VAS) pain value ≥40 and \<95 at screening. * Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury,...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859, LY3556050, LY3526318, LY3857210, LY4065967 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
LY3848575 is an investigational small molecule being studied for neuropathic pain, specifically painful distal sensory polyneuropathy. It has been evaluated in a Phase 2 clinical trial in adults with this condition. It is not approved for any indication and remains in clinical development.
LY3848575 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the drug in neuropathic pain.
LY3848575 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA or any other regulatory agency.
LY3848575 has been studied in one completed Phase 2 trial, NCT06568042, titled Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy. The trial enrolled 558 participants across the United States, Canada, Germany, Japan, Mexico, Poland, and South Korea.
The Phase 2 trial NCT06568042 was a randomized, double-blind, placebo-controlled study. It enrolled 558 adults aged 18 and older with painful distal sensory polyneuropathy. Participants were not healthy volunteers, and the study has been completed.